[go: up one dir, main page]

AR004701A1 - 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo. - Google Patents

2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.

Info

Publication number
AR004701A1
AR004701A1 ARP960104954A ARP960104954A AR004701A1 AR 004701 A1 AR004701 A1 AR 004701A1 AR P960104954 A ARP960104954 A AR P960104954A AR P960104954 A ARP960104954 A AR P960104954A AR 004701 A1 AR004701 A1 AR 004701A1
Authority
AR
Argentina
Prior art keywords
composition
compounds
preparation
equipment
pharmaceutical composition
Prior art date
Application number
ARP960104954A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR004701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR004701A1 publication Critical patent/AR004701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2-azetidinonas hipocolesterolemicas substituidas con azucares, asi como tambien composiciones farmaceuticas que los contienen, proceso para lapreparacion de dicha composicion, uso de dichos compuestos para fabricar mediamentos y un equipopara la combinacion de un agente de 2-azetidinonassubstituidas con azucar, reductor del colesterol, y un inhibidor de la biosintesis del colesterol,para el tratamiento y prevencion de laarteriosclerosis. Dichos compuestos tienen la formulae structural (I) en donde: R26 es H o OG1; G y G1 son independientemente seleccionados que consiste enH(formula II) siempre que cuando R26 es H o OH, G no sea H siendo Ar1, R1, Q, definidos en la memoria descriptiva.
ARP960104954A 1995-10-31 1996-10-29 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo. AR004701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US818595P 1995-10-31 1995-10-31
US57084795A 1995-12-12 1995-12-12

Publications (1)

Publication Number Publication Date
AR004701A1 true AR004701A1 (es) 1999-03-10

Family

ID=26677904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104954A AR004701A1 (es) 1995-10-31 1996-10-29 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.

Country Status (27)

Country Link
EP (1) EP0877750B1 (es)
JP (2) JP3385031B2 (es)
KR (1) KR100311554B1 (es)
CN (1) CN1103780C (es)
AR (1) AR004701A1 (es)
AT (1) ATE219495T1 (es)
AU (1) AU712158B2 (es)
BR (2) BR9612998B1 (es)
CA (1) CA2235943C (es)
CY (1) CY2353B1 (es)
CZ (1) CZ293957B6 (es)
DE (1) DE69621952T2 (es)
DK (1) DK0877750T3 (es)
ES (1) ES2175141T3 (es)
GE (1) GEP20033006B (es)
HU (1) HU226822B1 (es)
ID (1) ID16177A (es)
IL (1) IL124268A (es)
MX (1) MX9803447A (es)
MY (1) MY114803A (es)
NO (1) NO311692B1 (es)
NZ (1) NZ321766A (es)
PL (1) PL184698B1 (es)
PT (1) PT877750E (es)
SK (1) SK283552B6 (es)
TW (1) TW448181B (es)
WO (1) WO1997016455A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
PE20020718A1 (es) * 2000-12-20 2002-08-09 Schering Corp 2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR100833089B1 (ko) * 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE331512T1 (de) * 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
JP2004517920A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CN1275949C (zh) 2001-03-28 2006-09-20 先灵公司 2－吖丁啶酮中间体化合物的对映体选择性合成
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
JP2007509963A (ja) * 2003-10-30 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血漿薬としての２−アゼチジノン
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
JP2008539255A (ja) * 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) * 1993-04-23 1994-10-24 Allan W. Rey N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
BR9612998B1 (pt) 2010-03-23
CZ293957B6 (cs) 2004-08-18
CA2235943C (en) 2002-10-01
CN1205707A (zh) 1999-01-20
JP3385031B2 (ja) 2003-03-10
DE69621952T2 (de) 2003-01-16
CN1103780C (zh) 2003-03-26
KR19990067202A (ko) 1999-08-16
BR9611401A (pt) 1999-01-05
KR100311554B1 (ko) 2002-06-20
HU226822B1 (en) 2009-11-30
HUP9802539A2 (hu) 1998-11-30
PL184698B1 (pl) 2002-12-31
JPH10512592A (ja) 1998-12-02
TW448181B (en) 2001-08-01
GEP20033006B (en) 2003-07-10
DK0877750T3 (da) 2002-07-15
MX9803447A (es) 1998-09-30
HUP9802539A3 (en) 1999-12-28
ID16177A (id) 1997-09-11
ES2175141T3 (es) 2002-11-16
ATE219495T1 (de) 2002-07-15
SK283552B6 (sk) 2003-09-11
SK48398A3 (en) 1998-11-04
HK1012507A1 (en) 1999-08-06
NZ321766A (en) 1999-07-29
CZ129498A3 (cs) 1998-10-14
EP0877750B1 (en) 2002-06-19
JP2001048895A (ja) 2001-02-20
PT877750E (pt) 2002-09-30
IL124268A (en) 2005-08-31
DE69621952D1 (de) 2002-07-25
PL327987A1 (en) 1999-01-04
AU712158B2 (en) 1999-10-28
NO311692B1 (no) 2002-01-07
NO981950L (no) 1998-06-26
CA2235943A1 (en) 1997-05-09
WO1997016455A1 (en) 1997-05-09
MY114803A (en) 2003-01-31
NO981950D0 (no) 1998-04-29
EP0877750A1 (en) 1998-11-18
AU7517996A (en) 1997-05-22
CY2353B1 (en) 2004-06-04
BR9611401B1 (pt) 2010-08-10

Similar Documents

Publication Publication Date Title
AR004701A1 (es) 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.
TR199901578T2 (xx) Klaritromisin form 0 kristali
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
ATE42959T1 (de) Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten.
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
BR0312464A (pt) Inibidores de tirosina quinases
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
ZA875179B (en) Taxol derivatives,their preparation and pharmaceutical compositions containing them
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
EP1857105A3 (en) Cathartic composition
CA2188043A1 (en) 7,11 disubstituted camptothecin derivatives, formulations containing such derivatives and their use
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
ES2100335T3 (es) Derivados de benzopirano y fenol para empleo como agentes inmunoestimulantes.
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
ES2156120T3 (es) Derivados arilamidicos.
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.

Legal Events

Date Code Title Description
FC Refusal